Osteosarcoma of the jaw – experience at the Medical University Vienna and comparative study with international tumor registries

OBJECTIVES: Osteosarcoma of the jaw (OSAJ) is fundamentally different in clinical practice from its peripheral counterparts. Studies are difficult to conduct due to low incidence rates. The primary aim of this study was to provide for the first time a comprehensive retrospective analysis of the treatment concepts and outcome data of OSAJ patients treated at the University Hospital Vienna and to compare these with two recently published studies on OSAJ. The clinical study was accompanied by a biomarker study investigating the prognostic relevance of melanoma-associated antigen-A (MAGE-A) in OSAJ specimens. METHOD: Eighteen patients were included, and their outcomes were compared to published data. Immunohistochemistry was performed with mouse monoclonal antibodies against MAGE-A. Survival rates were estimated by the Kaplan-Meyer method. The log-rank test was used to analyze potential prognostic parameters. Fisher’s exact test was performed to define the significant differences between the survival rates of the current study and the DOESAK registry. RESULTS: Disease-specific survival was 93.8% after five and 56.3% after ten years. The development of metastases (p=0.033) or relapse (p=0.037) was associated with worsened outcomes in our group as well as in the comparative group. Despite the different treatment concepts of the study groups, survival rates were comparable. MAGE-A failed to show prognostic relevance for OSAJ patients. CONCLUSIONS: Uncertainties about the optimal treatment strategies of OSAJ patients will currently remain. Thus, prospective studies of OSAJ are needed but are only feasible in a multicenter study setting, conducted over a prolonged time period

Osteosarcoma of the jaw – experience at the Medical University Vienna and comparative study with international tumor registries

OBJECTIVES: Osteosarcoma of the jaw (OSAJ) is fundamentally different in clinical practice from its peripheral counterparts. Studies are difficult to conduct due to low incidence rates. The primary aim of this study was to provide for the first time a comprehensive retrospective analysis of the treatment concepts and outcome data of OSAJ patients treated at the University Hospital Vienna and to compare these with two recently published studies on OSAJ. The clinical study was accompanied by a biomarker study investigating the prognostic relevance of melanoma-associated antigen-A (MAGE-A) in OSAJ specimens. METHOD: Eighteen patients were included, and their outcomes were compared to published data. Immunohistochemistry was performed with mouse monoclonal antibodies against MAGE-A. Survival rates were estimated by the Kaplan-Meyer method. The log-rank test was used to analyze potential prognostic parameters. Fisher’s exact test was performed to define the significant differences between the survival rates of the current study and the DOESAK registry. RESULTS: Disease-specific survival was 93.8% after five and 56.3% after ten years. The development of metastases (p=0.033) or relapse (p=0.037) was associated with worsened outcomes in our group as well as in the comparative group. Despite the different treatment concepts of the study groups, survival rates were comparable. MAGE-A failed to show prognostic relevance for OSAJ patients. CONCLUSIONS: Uncertainties about the optimal treatment strategies of OSAJ patients will currently remain. Thus, prospective studies of OSAJ are needed but are only feasible in a multicenter study setting, conducted over a prolonged time period

Prognostic Impact of Pretreatment Plasma Fibrinogen in Patients with Locally Advanced Oral and Oropharyngeal Cancer - Fig 1

<p><b>Receiver operating characteristic curves for pretreatment plasma fibrinogen predicting overall survival (A), and recurrence-free survival (B).</b> Using ROC curve analysis, a pretreatment plasma fibrinogen cutoff value of 447mg/dL was determined for both OS and RFS.</p

Correlation between pretreatment plasma fibrinogen levels and clinicopathological parameters in 183 patients with oral and oropharyngeal cancer.

<p>Correlation between pretreatment plasma fibrinogen levels and clinicopathological parameters in 183 patients with oral and oropharyngeal cancer.</p

Univariate and multivariate analysis of prognostic factors for overall survival and recurrence-free survival in patients with oral and oropharyngeal cancer.

<p>Univariate and multivariate analysis of prognostic factors for overall survival and recurrence-free survival in patients with oral and oropharyngeal cancer.</p

Kaplan–Meier estimates of the probability of overall survival in 183 patients with locally advanced OOSCC according to low and high pretreatment plasma fibrinogen.

<p>Kaplan–Meier estimates of the probability of overall survival in 183 patients with locally advanced OOSCC according to low and high pretreatment plasma fibrinogen.</p

Kaplan–Meier estimates of the probability of recurrence-free survival in 183 patients with locally advanced OOSCC according to low and high pretreatment plasma fibrinogen.

<p>Kaplan–Meier estimates of the probability of recurrence-free survival in 183 patients with locally advanced OOSCC according to low and high pretreatment plasma fibrinogen.</p